Ankylosing Spondylitis News

July 6, 2020July 6, 2020

CHMP Favors At-home Injection Form of Remsima for Europe

Ankylosing Spondylitis News, COVID-19 News

The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), is recommending the use of a subcutaneous (under the skin) injection formulation of ... Read more

June 22, 2020June 22, 2020

Simponi Effective, Including in Patients Who Tried Other TNF Blockers, Data Show

Ankylosing Spondylitis News

Simponi (golimumab) — a TNF inhibitor — is an effective therapy for people with ankylosing spondylitis (AS) and other chronic inflammatory conditions, regardless of pre-treatment with other TNF inhibitors, real-world data from Germany ... Read more

June 18, 2020June 18, 2020

Cosentyx Approved in US to Treat Active nr-axSpA

Ankylosing Spondylitis News

Cosentyx (secukinumab) has been approved in the U.S. to treat people with active non-radiographic axial spondyloarthritis (nr-axSpA), its developer, Novartis, has announced. The approval by the U.S. Food and Drug ... Read more

June 15, 2020June 15, 2020

Nepexto, Enbrel Biosimilar, Approved to Treat Patients in Europe

Ankylosing Spondylitis News

Nepexto, a biosimilar to Enbrel (etanercept), has been approved by the European Commission to treat ankylosing spondylitis (AS) and several other inflammatory disorders. The therapy, co-developed by Mylan and Lupin, is expected ... Read more

June 10, 2020July 11, 2020

Coalition Will Address Racial Disparities in Rare Disease Communities

Ankylosing Spondylitis News, COVID-19 News

The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for ... Read more

June 8, 2020June 10, 2020

FDA Approves Taltz for Non-radiographic Axial Spondyloarthritis

Ankylosing Spondylitis News, COVID-19 News

Eli Lilly‘s Taltz (ixekizumab) has been approved in the U.S. to treat non-radiographic axial spondyloarthritis (nr-axSpA) in people who have objective signs of inflammation. “This approval reflects Lilly’s continued growth ... Read more

May 28, 2020June 28, 2020

COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say

Ankylosing Spondylitis News, COVID-19 News

While the ongoing COVID-19 pandemic won’t have much of an impact on cash available for new biotech startups, it has begun to cause delays in the development of gene therapies ... Read more

May 25, 2020June 25, 2020

Eurordis Urges Expansion of Newborn Screening Initiatives Across Europe

Ankylosing Spondylitis News

European authorities must step up efforts to screen babies for a multitude of genetic disorders, a panel of experts suggested during a May 14-15 online medical conference. The session was ... Read more

May 20, 2020June 20, 2020

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

Ankylosing Spondylitis News, COVID-19 News

Eurordis, a Paris-based coalition of national rare disease associations across Europe, hosted its first all-virtual conference, bringing some 1,500 delegates from 57 countries together online during the COVID-19 pandemic. The ... Read more

May 12, 2020June 13, 2020

Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

Ankylosing Spondylitis News, COVID-19 News

The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey ... Read more

May 4, 2020May 4, 2020

Humira, Smoking Can Alter Gut Microbiome in AS, Study Finds

Ankylosing Spondylitis News

Both treatment with Humira (adalimumab) and smoking can alter the composition of the gut microbiome — the microorganisms living in the gut — in people with ankylosing spondylitis (AS), a new study shows. ... Read more

April 27, 2020April 27, 2020

High Levels of Protein Found in Bones and Gut May Link AS and IBD

Ankylosing Spondylitis News

Elevated levels of a protein produced in both bones and the gut, known as lipocalin 2 (LCN2), could explain the overlap between ankylosing spondylitis (AS) and inflammatory bowel disease (IBD), ... Read more

April 20, 2020April 20, 2020

TNF Inhibitor Use May Raise Risk of MS and Neuropathy in AS Patients

Ankylosing Spondylitis News

Use of tumor necrosis factor alpha (TNF) inhibitors is linked to a higher risk of inflammatory disorders affecting the nervous system among people with ankylosing spondylitis (AS) and psoriatic arthritis (PsA), ... Read more

April 13, 2020April 13, 2020

TNF Inhibitors Often Ineffective, Affecting Certain Aspects of Life for AS Patients, Study Says

Ankylosing Spondylitis News

Treatment with tumor necrosis factor inhibitors (TNFi) is not effective for many patients with ankylosing spondylitis (AS), causing them to switch therapies and leading to lower quality of life and ... Read more

April 6, 2020April 6, 2020

CHMP Supports Cosentyx’s Approval in Europe to Treat nr-axSpA

Ankylosing Spondylitis News

The Committee for Medicinal Products for Human Use (CHMP) is recommending the approval of Cosentyx (secukinumab) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Recommendations from CHMP, ... Read more